NOTE: Links to other websites open a new browser window; close that window to return to this page.
Gynuity Health Projects is a research and technical assistance organization dedicated to the idea that all people should have access to the fruits of medical science and technology development.
Gynuity works globally with a particular emphasis on resource-poor environments and underserved populations. Gynuity conducts research on the use of existing technologies; develops and introduces new technologies; disseminates scientific information to policymakers, reproductive health professionals, and the public; and generates data for regulatory filings while working with regulatory agencies.
Gynuity Health Projects recently joined with the Reproductive Health Technologies Project to convene expert meetings evaluating the use of misoprostol for abortion induction and for the treatment of incomplete abortion and miscarriage. Professionals with epidemiological, clinical and programmatic expertise reached consensus on the appropriate use of misoprostol based on the best current information. The results can be found in a series of documents called "Instructions for Use."
Please Note: The National Abortion Federation's Clinical Policies Board Committee has reviewed the "Consensus Statement: Instructions for use - Abortion Induction with Misoprostol (Cytotec®) in Pregnancies up to 9 Weeks LMP" produced by Gynuity Health Project and Reproductive Health Technologies Project. The misoprostol-only regimens described in this document are effective for medical abortion up to 9 weeks LMP, though mifepristone/misoprostol regimens are 5-10% more effective and seem to have significantly fewer gastrointestinal side effects.